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ABSTRACT
Objective: To determine whether a diagnosis of polymyalgia rheumatica (PMR) is associated with 
premature mortality. 
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Methods: We extracted anonymised electronic medical records of patients over the age of 40 
years, who were eligible for linkage with the Office for National Statistics (ONS) Death 
Registration dataset, from the Clinical Practice Research Datalink from 1990-2016. Patients with 
PMR were individually matched by age, sex and registered General Practice with up to 5 controls 
without PMR. The total number and proportion of deaths and mortality rates were calculated. The 
mortality rate ratio (MRR), with 95% confidence interval (CI), adjusted for age, sex, region, 
smoking status, body mass index (BMI), and alcohol consumption, was calculated using Poisson 
regression. The twenty most common causes of death were tabulated. 
Results: 18,943 patients with PMR were matched to 87,801 controls. Mean (standard deviation) 
follow-up after date of diagnosis was 8.0 (4.4) years in patients with PMR, and 7.9 (4.6) in 
controls. PMR was not associated with an increase in the risk of death (adjusted MRR 1.00 [95% 
CI 0.97, 1.03]) compared to matched controls. Causes of death were broadly similar between 
patients with PMR and controls, although patients with PMR were slightly more likely to have a 
vascular cause of death recorded (24% vs 23%).
Conclusions: A diagnosis with PMR does not appear to increase the risk of premature death. 
Minor variations in cause of death were observed, but overall this study is reassuring for patients 
with PMR and clinicians.
SIGNIFICANCE AND INNOVATIONS
1. This is the largest ever study of mortality among patient with polymyalgia rheumatica, 
including over 100,000 patients and controls
2. Polymyalgia rheumatica does not increase the risk of premature death
3. The cause of death is similar among patients with polymyalgia rheumatica compared to 
controls
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INTRODUCTION
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that predominantly affects 
older people, (1) and can have a devastating impact on patients’ lives. Classical symptoms of PMR 
include stiffness, pain and impairment to daily activities. (2) A recent study of PMR epidemiology 
estimated the incidence and prevalence of PMR to be 95.9 [94.9, 96.8] per 100,000 person years 
and 0.85% respectively. (1)
A recent systematic review found that patients with PMR had a higher burden of comorbid disease 
when compared to age and sex matched controls. (3) However, three previous studies reported no 
difference or reduced premature mortality among patients diagnosed with PMR. (4–6)
Given the high burden of comorbid disease among patients with PMR, the raised systemic levels 
of inflammation associated with it, and the prolonged glucocorticoid (GC) therapy with which 
many patients with PMR are treated, it is important to ascertain whether a diagnosis of PMR is 
associated with an increased risk of premature mortality.
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PATIENTS AND METHODS
Data source
The National Health Service (NHS) provides healthcare to all UK residents, and 98% of people in 
the UK are registered with a General Practice. Around 90% of patient contacts in the UK occur in 
primary care. (7) We utilised data from the Clinical Practice Research Datalink (CPRD; version 
July 2017), which contains data from 17 million contributing patients across 718 (7.5% of the 
total) practices.  This database, containing electronic, coded information collected during the 
course of routine healthcare, is representative of the UK population in terms of age, sex and 
ethnicity (8) and has been used extensively for research. The CPRD’s Independent Scientific 
Advisory Committee (ISAC) approved this study, (protocol number: 17_203RA).  
The CPRD can be linked to death registration data from the Office for National Statistics (ONS). 
Only practices based in England are eligible for linkage and, of those, 75% have consented. (8) 
Where consent exists, patient level data is linked via NHS Digital to the other established data 
sources. 
The linkage between CPRD and death registration data is available from January 1998 until 
February 2018. This dataset also contains information on the official date of death, the date of 
registration of death, the underlying cause of death and any other contributing factors given. (9)
Definition of incident PMR
The exposed group were aged 40 years and over with a CPRD recorded PMR diagnosis. Each 
patient had a Read code diagnosis of PMR (N20 Polymyalgia rheumatica; N200.00 Giant cell 
arteritis with polymyalgia rheumatica) between 02/01/1998 and 01/01/2018 and two prescriptions 
of GCs, the first made within six months of PMR diagnosis, and the second within six months of A
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the first. This replicates previous CPRD PMR studies (10) and provides supporting information as 
to the accuracy of the diagnosis. In addition to these requirements, each had at least three years of 
continuous follow up prior to date of diagnosis with PMR (the index date). 
Selection of unexposed group
Each individual with PMR was matched with up to five unexposed people. The matching criteria 
employed were: 1) year of birth +/- 3 years, 2) sex and 3) registered practice. The index date for 
each exposed person was assigned to their matched unexposed group, who were also required to 
have been contributing data on that date and for 3 years prior. 
Study period
The start of this study was defined as the index date, which was the date of PMR diagnosis for the 
exposed and their matched group. Follow up continued until the earliest of these events: 1) 1st 
January 2018 (the end of the period encompassed by ONS Death Registration data), 2) the date 
when a patient transferred out of the practice, 3) the last date of data collection from the practice, 
or 4) the date of death. 
Statistical analysis
Descriptive statistics were used to find average age of the exposed and unexposed as well as the 
proportion of exposed and unexposed per region, sex, smoking status, BMI category, alcohol 
consumption status, as well as follow up prior to, and following, index date. This was to ensure 
that the exposed and unexposed were similar. 
The primary outcome measures were total number of deaths in exposed and unexposed groups, as 
well as estimated mortality rate per 1,000 person years (with 95% confidence intervals [CI]). 
Estimates of survival were constructed using Kaplan-Meier methods. ONS Death Registration data 
includes the date of death, the date of death registration and cause of death. For this study the date 
of death was used and the cause of death was included as a secondary analysis.A
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A Poisson regression model was used to calculate the mortality rate ratio (MRR) with 95% CI in 
order to compare the mortality rate of patients with PMR to those without. This figure was 
adjusted for age, sex, region, smoking status, BMI, and alcohol consumption. If data regarding 
covariates were missing, patients were assumed to be non-smokers, consume no alcohol and have 
a normal BMI.
RESULTS
A total of 18,943 patients with PMR and 87,801 matched unexposed individuals were included in 
the analysis. The demographic information of patients is presented in table 1. The average age at 
diagnosis, sex and region of GP practice were very similar between the exposed and unexposed. 
The mean age of the exposed was greater than the unexposed by 0.3 years, and the mean (standard 
deviation) follow up period was 7.9 (4.6) years. The three disease risk modifiers, BMI, smoking 
and alcohol consumption, were similar between the exposed and unexposed, however data were 
less likely to be missing in the exposed compared to unexposed.
The total number, and proportion, of patients with and without PMR who died, as well as the 
mortality rate ratio and twenty most common causes of death, are shown in table 2. Figure 1 
describes the Kaplan Meier estimate of mortality in the first ten years after diagnosis in patients 
with and without PMR. Over the whole time period, a slightly higher proportion of patients with 
PMR died compared to patients without PMR (31.9% and 31.0%). However, the mortality rates A
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were similar, at 39.9 and 39.2 per 1,000 patient years and the mortality rate ratio of 1.00 (0.97, 
1.03), which was adjusted for age, sex, region, smoking status, BMI, and alcohol consumption, 
showed there was no difference between the two groups. A sensitivity analysis where patients with 
co-existent GCA were excluded from the sample found the same results.
DISCUSSION
Main findings
This study confirms that a diagnosis of PMR does not have a significant impact on life 
expectancy. The causes of death in patients with PMR were broadly similar to those of matched 
controls; however a slightly higher proportion of patients with PMR died due to vascular causes 
and a slightly lower proportion died due to neoplastic conditions. 
Strengths and limitations 
This is the largest study to estimate the effect that a diagnosis of PMR has upon life expectancy. 
The sample used a large, established database of patients who are representative of the UK 
population, (11) and is drawn from primary care, where the majority of patients with PMR are 
managed. (12) The Office for National Statistics (ONS) is the UK’s recognised national statistical 
institute. All deaths in the UK must be registered and are therefore recorded in this dataset. This 
data source is used to report trends in mortality and guide national healthcare policy. Therefore, 
the ONS dataset is the most complete source of this information.
A potential limitation is the initial ascertainment of PMR. In CPRD it is not possible to 
authenticate diagnoses by ensuring each patient fulfils validated classification criteria for PMR. 
No diagnostic criteria nor specific diagnostic test exists for PMR, therefore even if access to A
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individual patients were possible, confirmation of diagnosis can never be fully achieved. However, 
ensuring that all patients have at least two GC prescriptions in their records provides more 
confidence in the diagnosis of PMR. This method has been used before in previously published 
studies in CPRD of PMR. (13) Furthermore, this study can provide reassurance for patients with a 
diagnosis with PMR that no association with premature mortality was found. 
The cause of death may be incorrectly coded. Some studies have estimated for example that 
cardiovascular causes of death may be overstated in mortality data. (14) However, a study from 
the ONS found that only 12% of the broad underlying causes of death needed to be amended 
following medical examiner scrutiny. (15) Furthermore, there is no reason to suppose that the 
presence of PMR would lead to a difference in error rate compared to those without.
Another potential bias is surveillance bias, wherein people who are diagnosed with PMR may be 
more likely to be followed up more closely in primary care. This would mean that comorbidities 
may be diagnosed sooner and treated more effectively in these patients, which could lead to 
improvement in survival, mitigating any potential reduction in survival caused by the disease 
itself. 
Previous studies have found that patients with PMR have a high comorbidity burden, with a 
possible increased risk of vascular disease. (3,16) In this study, a greater proportion of patients 
with PMR had a vascular cause of death recorded. Conversely, a smaller proportion of patients 
with PMR were recorded as dying due to cancer. Therefore, the neutral effect of PMR on mortality 
observed in the current study may be caused by the increase in the risk of vascular disease in this 
patient group balancing the reduction in the risk of death due to cancer among patients with PMR. 
Comparison to other studies 
Two previous studies based in Norway have reported reduced mortality rates in patients with PMR 
and attributed this to improved medical surveillance among patients with PMR. (4,5) One study 
from the United States however found no significant difference in mortality in patients with PMR 
when compared to the general population, (6) while another more recent study with more than 40 
years of data also concluded that survival among patients with PMR was no worse compared to 
the general population. (17) In this study, no significant difference in mortality, between patients A
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with PMR compared to matched controls, was found, with an adjusted mortality rate ratio of 1.00 
[0.97, 1.03]. This study is therefore reassuring for those who receive a diagnosis of PMR. 
Conclusion and clinical implications 
This study is the first to estimate the effect that PMR has on mortality in a large sample of patients 
using primary care and linked data. Overall, the mortality rate in patients with PMR, when 
compared to matched controls, is not significantly different, although there are some minor 
variations in the recorded cause of death. 
Our previous work has demonstrated that patients with PMR were less likely than controls to have 
a previous diagnosis of cancer or neurological diseases. Therefore, it could be speculated that 
patients with PMR group should actually have improved survival when compared to matched 
controls. The neutral effect observed may be due to increased rates of vascular disease in patients 
with PMR balancing the reduction in risk of death due to cancer. 
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Table 1: Demographic information of included patients
Total Exposed Unexposed
Age
Mean (SD) 73.6 (8.9) 73.8 (9.1) 73.5 (8.9)
Sex (%)
Male 34,559 (32.4) 6,273 (33.1) 28,286 (32.2)
Female 72,185 (67.6) 12,670 (66.9) 59,515 (67.8)
Region (%)
North East 1,740 (1.6) 306 (1.6) 1,434 (1.6)
North West 13,428 (12.6) 2,366 (12.5) 11,062 (12.6)
Yorkshire & the Humber 3,574 (3.4) 639 (3.4) 2,935 (3.3)
East Midlands 2,853 (2.7) 499 (2.6) 2,354 (2.7)
West Midlands 15,032 (14.1) 2,609 (13.8) 12,423 (14.1)
East of England 15,320 (14.4) 2,674 (14.1) 12,646 (14.4)
South West 17,137 (16.1) 3,042 (16.1) 14,095 (16.1)
South Central 14,075 (13.2) 2,517 (13.3) 11,558 (13.2)
London 7,732 (7.2) 1,456 (7.7) 6,276 (7.1)
South East Coast 15,853 (14.9) 2,835 (15.0) 13,018 (14.8)
BMI category
Normal(18.5-24.9) 34,552 (32.4) 6,052 (31.9) 28,500 (32.5)
Underweight (<18.5) 1,986 (1.9) 0,221 (1.2) 1,765 (2)
Overweight (25-29.9) 36,515 (34.2) 6,923 (36.5) 29,592 (33.7)
Obese (>=30) 21,521 (20.2) 4,132 (21.8) 17,389 (19.8)
Missing 12,170 (11.4) 1,615 (8.5) 10,555 (12)
Smoking
Non-smoker 90,111 (84.4) 16,582 (87.5) 73,529 (83.8)
Smoker 11,823 (11.1) 1,827 (9.6) 9,996 (11.4)
Missing 4,810 (4.5) 0,534 (2.8) 4,276 (4.9)
Alcohol
Never / no current 21,546 (20.2) 3,779 (19.9) 17,767 (20.2)
<10 units per week 55,927 (52.4) 10,369 (54.7) 45,558 (51.9)A
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Total Exposed Unexposed
10 or more units per week 16,133 (15.1) 2,942 (15.5) 13,191 (15)
Missing 13,138 (12.3) 1,853 (9.8) 11,285 (12.9)
Follow up (years)
Mean (SD) 7.9 (4.6) 8.0 (4.4) 7.9 (4.6)
Table 2: Number, proportion and cause of death (in order of frequency) in patients with and 
without PMR 
Exposed N (%) Unexposed N (%)
Total number of deaths 6,046 
(31.9)
Total number of deaths 27,224 (31.0)
Rate per 1,000 patient years 
(95% CI)
39.9 (38.9, 
41)
Rate per 1,000 patient 
years (95% CI)
39.2 (38.7, 
40)
Mortality rate ratio (95% CI) 1.00 (0.97, 1.03)
Causes of death
1 Chronic ischaemic 
heart disease
464 (7.7) Chronic ischaemic heart 
disease
1,810 (6.7)
2 Acute myocardial 
infarction
409 (6.8) Chronic obstructive 
pulmonary disease
1,652 (6.1)
3 Chronic obstructive 327 (5.4) Acute myocardial 1,651 (6.1)A
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Exposed N (%) Unexposed N (%)
pulmonary disease infarction
4 Malignant neoplasm: 
Bronchus or lung
316 (5.2) Malignant neoplasm: 
Bronchus or lung
1,631 (6.0)
5 Bronchopneumonia 258 (4.3) Bronchopneumonia 989 (3.6)
6 Pneumonia 243 (4.0) Atherosclerotic heart 
disease
967 (3.6)
7 Atherosclerotic heart 
disease
187 (3.1) Pneumonia 889 (3.3)
8 Vascular dementia 123 (2.0) Alzheimer disease 790 (2.9)
9 Urinary tract infection 115 (1.9) Malignant neoplasm: 
Breast
709 (2.6)
10 Malignant neoplasm: 
Pancreas
109 (1.8) Vascular dementia 604 (2.2)
11 Cerebrovascular 
disease
108 (1.8) Cerebrovascular disease 585 (2.2)
12 Alzheimer disease 106 (1.8) Malignant neoplasm 
without specification
460 (1.7)
13 Malignant neoplasm 
without specification.
103 (1.7) Malignant neoplasm: 
Pancreas
447 (1.6)
14 Malignant neoplasm: 
Breast
99 (1.6) Urinary tract infection 416 (1.5)
15 Other interstitial 
pulmonary diseases
93 (1.5) Malignant neoplasm: 
Colon
410 (1.5)
16 Congestive heart failure 84 (1.4) Malignant neoplasm: 
Oesophagus
371 (1.4)
17 Malignant neoplasm: 
Colon
84 (1.4) Malignant neoplasm: 
Bladder
312 (1.2)
18 Aortic (valve) stenosis 71 (1.2) Congestive heart failure 309 (1.1)
19 Cerebral infarction 68 (1.1) Intracerebral 
haemorrhage
302 (1.1)
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Exposed N (%) Unexposed N (%)
20 Malignant neoplasm: 
oesophagus
67 (1.1) Other respiratory 
disorders
291 (1.1)
Others 2,612 
(43.8)
Others 11,629 (41.6)
Figure 1: Kaplan-Meier survival plot of patients with and without PMR 
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